IRIS
MOIA, RICCARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.423
EU - Europa 2.506
AS - Asia 1.752
SA - Sud America 236
Continente sconosciuto - Info sul continente non disponibili 152
AF - Africa 88
OC - Oceania 4
Totale 8.161
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.224
RU - Federazione Russa 754
IT - Italia 637
SG - Singapore 566
IE - Irlanda 293
CN - Cina 289
HK - Hong Kong 253
DE - Germania 214
VN - Vietnam 202
BR - Brasile 192
BD - Bangladesh 188
SE - Svezia 141
FR - Francia 132
GB - Regno Unito 113
CA - Canada 99
IN - India 85
UA - Ucraina 47
FI - Finlandia 41
BJ - Benin 40
KR - Corea 39
MX - Messico 35
PL - Polonia 27
ID - Indonesia 22
JP - Giappone 22
TR - Turchia 20
ZA - Sudafrica 17
LT - Lituania 16
ES - Italia 15
AT - Austria 14
NL - Olanda 13
AR - Argentina 12
IQ - Iraq 12
CR - Costa Rica 11
CO - Colombia 9
EC - Ecuador 9
EE - Estonia 9
PH - Filippine 9
SA - Arabia Saudita 9
CZ - Repubblica Ceca 8
ET - Etiopia 8
JM - Giamaica 8
TT - Trinidad e Tobago 8
BE - Belgio 7
CW - ???statistics.table.value.countryCode.CW??? 7
SV - El Salvador 7
HN - Honduras 6
IR - Iran 6
NI - Nicaragua 6
VE - Venezuela 6
EG - Egitto 5
AU - Australia 4
GP - Guadalupe 4
GT - Guatemala 4
KE - Kenya 4
MD - Moldavia 4
MY - Malesia 4
PE - Perù 4
PK - Pakistan 4
PR - Porto Rico 4
UZ - Uzbekistan 4
AL - Albania 3
CL - Cile 3
DK - Danimarca 3
HR - Croazia 3
NG - Nigeria 3
SY - Repubblica araba siriana 3
AO - Angola 2
CH - Svizzera 2
DZ - Algeria 2
GR - Grecia 2
IL - Israele 2
KG - Kirghizistan 2
MA - Marocco 2
OM - Oman 2
PA - Panama 2
RS - Serbia 2
SC - Seychelles 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BM - Bermuda 1
BS - Bahamas 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
HU - Ungheria 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NP - Nepal 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SN - Senegal 1
TC - Turks e Caicos 1
TN - Tunisia 1
Totale 8.016
Salva come PNG Salva come JPEG
Città #
San Jose 486
Dublin 291
Council Bluffs 280
Hong Kong 250
Ashburn 244
Singapore 233
Columbus 122
Beijing 109
Los Angeles 106
Novara 79
New York 74
Jacksonville 73
Lauterbourg 70
Phoenix 67
Chandler 66
Moscow 65
Santa Clara 59
Ho Chi Minh City 56
Hanoi 50
Boardman 49
Milan 48
Munich 47
Buffalo 43
Cotonou 40
Piemonte 38
St Louis 36
Dallas 34
Princeton 34
Seoul 34
Toronto 34
Helsinki 33
Lawrence 33
Turin 32
Vercelli 32
Orem 29
San Bernardino 29
São Paulo 29
Chicago 27
Frankfurt am Main 27
Schaumburg 27
Bremen 25
Brooklyn 25
Atlanta 24
Houston 24
Mexico City 23
Warsaw 23
Falkenstein 22
Wilmington 22
Rome 21
Denver 20
Chennai 19
Grafing 19
Olathe 19
Tokyo 19
Tornaco 18
London 17
Boston 16
Montreal 16
Nuremberg 15
Poplar 15
Johannesburg 13
Podenzano 13
San Mateo 13
Hillsboro 12
Belo Horizonte 10
Mumbai 10
North Bergen 10
Ankara 9
Cassano Magnago 9
Genoa 9
Manchester 9
Naples 9
Redondo Beach 9
Addis Ababa 8
Bologna 8
Brasília 8
Charlotte 8
Haiphong 8
Roseto degli Abruzzi 8
Stockholm 8
Varese 8
Amsterdam 7
Augusta 7
City of London 7
Da Nang 7
Gallarate 7
Kingston 7
Miami 7
Ottawa 7
Rio de Janeiro 7
Shanghai 7
Turku 7
West Jordan 7
Ann Arbor 6
Bexley 6
Brno 6
Garland 6
Guangzhou 6
Hangzhou 6
Jakarta 6
Totale 4.242
Salva come PNG Salva come JPEG
Nome #
Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels 192
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia 169
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement 168
Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome 166
Targeting p53 in chronic lymphocytic leukemia 152
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 146
Active AKT signaling triggers CLL towards Richter's transformation via over-activation of Notch1 146
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 139
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma 135
A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation 132
An update on: molecular genetics of high-risk chronic lymphocytic leukemia 129
Precision medicine management of chronic lymphocytic leukemia 125
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity 125
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients 124
Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms 123
Druggable Molecular Pathways in Chronic Lymphocytic Leukemia 123
Potential of BCL2 as a target for chronic lymphocytic leukemia treatment 122
High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias 121
A Rare Case of Life-Threatening Jaundice Caused by Epstein-Barr Virus Infection and Secondary Cold Agglutinin Syndrome Successfully Treated with Rituximab 120
High reproducibility of spleen stiffness measurement by vibration-controlled transient elastography with a spleen-dedicated module 113
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome 113
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression 113
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 113
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations 112
Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination 111
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL 110
An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient 110
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 109
High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy 108
XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 107
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 107
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 106
Prevalence and clinical impact of clonal hematopoiesis of indeterminate potential (CHIP) in chronic lymphocytic leukemia and richter transformation 106
Prognostic value of clonal evolution identified by sequential FISH in untreated chronic lymphocytic leukaemia 103
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 101
The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications 100
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma 98
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment 98
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 98
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 97
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 97
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib 96
Liquid biopsy in hematological malignancies: current and future applications 96
Prognostication in chronic lymphocytic leukemia 95
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 95
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 95
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 93
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 93
Cerebrospinal fluid xanthochromia after pegasparaginase hepatotoxicity in B-cell acute lymphoblastic leukemia 91
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY 89
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 88
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation 85
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia 84
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 81
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA 80
Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities 79
Reply to Aron P. Kater et al 79
HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma 78
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 78
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 75
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside 73
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience 73
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma 72
Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV ‐Positive Patient: A Case Report 69
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation 67
Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy 67
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia 64
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands 63
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy 63
null 62
null 60
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial 50
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 50
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker 48
Diagnostic Challenges in a Young Man with a Suspected Mast Cell Disorder, Dysplastic Bone Marrow Morphology, and a ZRSR2 Mutation 48
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms 43
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial 39
Clonal hematopoiesis dynamics influences long‐term outcomes of follicular lymphoma: Results from FIL FOLL12 trial 39
Molecular Pathogenesis and Targeted Treatment of Richter Transformation 39
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes 34
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology 31
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 30
Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma 30
Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy 30
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R) 30
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study 30
Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study 29
No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12 26
Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring 23
Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics 21
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study 21
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL 20
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL) 20
Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice 17
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 16
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 14
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL 13
Totale 8.161
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.652
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.652
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022226 0 0 0 11 21 3 24 3 6 25 63 70
2022/2023633 43 33 51 10 39 44 32 30 277 6 51 17
2023/2024359 28 29 33 12 44 11 46 4 1 17 38 96
2024/2025997 16 12 70 14 37 51 89 224 188 85 37 174
2025/20264.059 176 126 217 442 425 277 563 606 305 336 372 214
2026/20271.614 276 425 424 489 0 0 0 0 0 0 0 0
Totale 8.161